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Objective: To determine clinical and economic outcomes following COPD-related hospitaliza-
tion/emergency department (ED) care in patients receiving COPD maintenance therapy.
Methods: In this retrospective, observational study using administrative claims data, we iden-
tified COPD patients age 40 years who received maintenance therapy within 30 days of an
initial COPD-related hospitalization or ED visit with: (1) fluticasone propionate/salmeterol
combination (FSC 250 mcg/50 mcg) as new therapy, or (2) an anticholinergic (AC; tiotropium
or ipratropium with or without albuterol). The FSC and AC patients were matched (1:3 ratio)
on various baseline characteristics using propensity scores to mitigate selection bias at base-
line. The proportion of patients with COPD-related healthcare events, the mean event rates,
and the mean costs in the subsequent 12 months were calculated.
Results: The FSC cohort (N Z 484) had a significantly lower proportion of rehospitalized
patients during follow-up than did the AC cohort (N Z 1452), 3.1% versus 4.6% (P Z 0.047).
The mean number of rehospitalizations was 0.03 in the FSC cohort and 0.07 in the AC cohort
(P Z 0.001). The proportion of patients with an exacerbation resulting in an ED or
physician-outpatient visit and the mean number of such visits did not differ between cohorts.
Total annual COPD-related medical costs were lower for FSC than for AC ($2080 versus $2636,
P Z 0.006), with lower medical and higher pharmacy costs.
Conclusions: Patients receiving FSC as maintenance therapy following an initial COPD-related
hospitalization or ED visit experienced better clinical and economic outcomes than patients
receiving AC.
ª 2011 Elsevier Ltd. All rights reserved.PD, chronic obstructive pulmonary disease; ED, emergency department; FSC, fluticasone propionate/
orticosteroid; IPR, ipratropium (alone or in fixed dose combination with albuterol); LABA, long-acting
atching; SABA, short-acting beta-agonist; TIO, tiotropium.
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830 A.A. Dalal et al.Introduction MethodsExacerbations are an important cause of morbidity and
mortality in COPD, and their prevention is a primary goal
in the medical management of chronic obstructive
pulmonary disease (COPD).1 In addition to producing acute
worsening of dyspnea, cough and sputum production,
exacerbations have sustained effects, including an accel-
erated decline in lung function,2,3 reduced health status
and quality of life4e7 and increased risk of death.8,9
Exacerbations can be triggered by viral or bacterial
infection, exposure to chemical irritants, and other
factors. Although mild exacerbations may be treated on an
outpatient basis with oral corticosteroids and/or antibi-
otics, patients frequently present to the emergency
department (ED) or are admitted to the hospital for
moderate or severe exacerbations that require more
intensive medical treatment. Prior research has shown
that patients with moderate or severe COPD average two
to more than three exacerbations per year.10 Exacerba-
tions are also costly, accounting for nearly 70% of the
direct healthcare costs of COPD.11 The cost of COPD-
related hospitalizations and ED visits were estimated to
be $10 billion in 2003.12
The frequency and severity of exacerbations increase
with the severity of the underlying COPD. An additional
characteristic of exacerbations is that they tend to cluster
together in time. Hurst and colleagues reported that about
one-third of exacerbations were recurrent ones and that
over a quarter of first exacerbations were followed by
a second exacerbation within eight weeks.13 Similarly,
a history of exacerbation in the prior year is predictive of
exacerbations in the current year.6 Furthermore,
a subgroup of patients has a distinct phenotype that
increases susceptibility to exacerbation independently of
disease severity.14 In the months after an exacerbation-
related hospitalization, the risk of rehospitalization is
high.15e19 However, appropriate drug therapy has been
shown to lower the risk for exacerbations.1 Thus, for
patients not already receiving maintenance therapy, it is
crucial that such therapy be initiated at the time a patient
is treated for an exacerbation.
Clinical guidelines recommend maintenance therapy
with a short- or long-acting anticholinergic agent (AC),
long-acting beta-agonist (LABA), inhaled corticosteroid
(ICS), or ICS þ LABA combination drug.1 Research indicates
that combination therapy with ICS þ LABA may be espe-
cially beneficial in preventing exacerbations due to the
differing therapeutic action of the two drugs (i.e., anti-
inflammatory and bronchodilatory activity, respectively)
compared to therapy with a single agent.20e24
The present retrospective cohort study examined COPD-
related rehospitalization and repeat ED visits in patients
who may or may not have been receiving maintenance
therapy at baseline and who experienced an exacerbation
event, which, in treated patients, can be considered
an indication of treatment failure. The main objective
was to assess whether initiation of FSC therapy, compared
to continued or new therapy with AC, impacts the occur-
rence of subsequent exacerbations following an initial
exacerbation.The primary objective of this retrospective cohort study of
COPD patients was to determine the risk of COPD-related
rehospitalization in patients who received continuing or
new maintenance therapy with AC or new therapy with FSC
within 30 days after discharge from an initial COPD-related
hospitalization or ED visit. Secondary objectives were to
determine risk for subsequent exacerbations requiring an
ED or physician-outpatient visit and to compare COPD-
related medical and prescription drug costs between the
groups.Data source
Data from January 1, 2003 through March 31, 2009 were
obtained from the Ingenix Impact National Benchmark
database, a comprehensive, healthcare claims database
that is generally representative of the U.S. insured pop-
ulation. It includes 1997e2010 data for more than 98
million lives covered by approximately 46 different health
plans. Together, these plans cover nine U.S. census regions.
Available data include enrollment and demographic infor-
mation; inpatient, outpatient and pharmacy claims; and
laboratory results. At least two years of medical and
pharmacy claims are available for 30.8 million persons and
at least three years of claims for 18.3 million patients. The
database is de-identified and compliant with the Health
Insurance Portability and Accountability Act (HIPAA).Patient selection
Eligible patientsmet the following criteria: (1) age40 years
on the index date, (2) continuously enrolled in a health plan
during the pre-index, treatment assessment, and follow-up
periods, (3) received maintenance therapy with FSC 250
mcg/50 mcg or AC within 30 days after an index event
identified between January 1, 2004 and January 31, 2008,
and (4) had not previously received maintenance therapy
with ICSþ LABA for COPD. Patients in the AC groupmay have
received AC in the pre-index period, as the study’s aimwas to
determine whether initiation of ICS-containing therapy
following an initial exacerbation is associated with different
outcomes than continued or new therapy with AC.
The index event was defined as a hospitalization with
a primary or secondary discharge diagnosis of COPD or an
ED visit with a primary diagnosis of COPD. The index date
was the date of discharge from the hospital or ED. A claim
with an ICD-9-CM code of 491.xx (chronic bronchitis),
492.xx (emphysema) or 496.xx (chronic airway obstruction)
was considered to represent a diagnosis of COPD. The 12-
month period prior to the index date was the “pre-index
period” and was used to determine patient baseline char-
acteristics. The 30-day period after the index date was the
“treatment assessment period” and was used to identify
patients receiving new therapy with FSC 250 mcg/50 mcg
(the dose approved for COPD maintenance therapy in the
United States) or continued or new therapy with AC. The
12-month period following the treatment assessment
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outcomes.
Patients were excluded from the study if they: (1) had
a potentially confounding disease or condition (respiratory
cancer, cystic fibrosis, fibrosis due to tuberculosis, bron-
chiectasis, pneumoconiosis, pulmonary fibrosis, pulmonary
tuberculosis, or sarcoidosis) during the pre-index, treat-
ment assessment or follow-up periods, (2) received a COPD
maintenance therapy drug other than their cohort’s study
drug during the treatment assessment period (potential FSC
patients were excluded if they had a prescription for AC,
FSC in a non-study dose [100 mcg/50 mcg or 500 mcg/
50 mcg] or budesonide/formoterol [another ICS þ LABA
combination product]; potential AC patients were excluded
if they had a prescription for ICS or LABA), (3) had a therapy
change during the treatment assessment period (defined as
switching maintenance therapies or augmenting the initial
maintenance therapy with a second maintenance therapy),
or (4) had a COPD-related exacerbation during the treat-
ment assessment period.
Propensity score-matching
The two cohorts were matched using propensity score-
matching (PSM) to mitigate selection bias in the absence of
randomization. The propensity score for a COPD patient
incorporated baseline demographic and clinical character-
istics and was defined as the probability of being treated
with FSC based on the individual’s covariate values at
baseline. Thus, if two persons, one in the FSC cohort and
the other in the AC cohort, had the same propensity score,
they would both have the same probability of being
assigned to the FSC cohort based on their overall disease
burden and COPD severity. After matching, the two groups
should be similar in terms of disease severity, comorbidity
profile, and prior healthcare utilization patterns and costs.
Matching was done using the technique of nearest available
matching on the estimated propensity score. The two
cohorts were matched using a 1:3 ratio of FSC to AC
patients and matching was performed up to three decimal
places (0.001).
Demographic and clinical variables in the pre-index
period that were included in the matching model were
age, sex and geographic region; Charlson comorbidity
index; a diagnosis of asthma, depression, upper respiratory
tract infection (URTI), lower respiratory tract infection
(LRTI), or cardiovascular disease (CVD); number of
prescription drug classes; number of different prescrip-
tions; number of COPD maintenance therapy drug classes;
number of short-acting beta-agonist (SABA) canisters
dispensed; oral corticosteroid prescription; home oxygen
therapy; occurrence of any COPD-related exacerbation
event; and type of study index event. The Dartmouth-
Manitoba adaption of the Charlson comorbidity index was
used,25e28 with COPD excluded when calculating scores.
Higher scores represent a higher burden of comorbidity.
Outcomes
The outcomes evaluated were healthcare events repre-
senting exacerbations of COPD that occurred during the 12-month period following the index event and 30-day post-
event treatment assessment period. The primary outcome
assessed was hospitalization with a primary discharge
diagnosis of COPD (ICD-9 code 491.xx, 492.xx or 496.xx).
Secondary outcomes assessed were ED visit (with a primary
diagnosis of COPD); physician-outpatient visit (defined as
a visit with a primary diagnosis of COPD that was followed
by a prescription fill for an antibiotic or oral corticosteroid
within five days); a combined endpoint of hospitalization or
ED visit; a combined endpoint of hospitalization or ED visit
or physician-outpatient visit; the number of exacerbation-
related healthcare events; and COPD-related healthcare
costs (pharmacy, medical and total costs) during the follow-
up period. Medical costs included healthcare facility
charges; professional services charges; and laboratory,
radiology and other outpatient procedures with a primary
diagnosis of COPD.
Analysis
A descriptive analysis of the cohorts at baseline was done
using standard summary statistics, such as means and
proportions. Inferential statistics were used to describe and
quantify inter-cohort differences in baseline characteristics
before the cohorts were matched on propensity score. For
categorical variables, chi-square test was used; for
continuous variables, T-test or Wilcoxon-Mann Whitney test
was used, as appropriate to the distribution.
The success of the propensity score-matching to reduce
bias was assessed by evaluating the standardized differ-
ences in the covariates between the two cohorts after
matching. For each covariate, the standardized difference
percent (di) was calculated as:
diZ100  ðxi  xniÞ
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where xi and xni are the sample means of the ith covariate
in the FSC and AC cohorts, respectively, and s2i and s
2
ni are
the corresponding sample variances. A standardized
difference of <10% is considered an acceptable level of
difference (or supports the assumption of balance)
between the comparison cohorts.29
The proportion of patients with a COPD exacerbation
event in the follow-up period and the mean number of
events were calculated. The Wilcoxon signed-rank test was
used to assess differences in the number of exacerbation
events. The McNemar’s test was used to assess differences
in the proportions of patients experiencing an exacerbation
event.
Mean COPD-related medical, pharmacy and total costs
(the sum of medical and pharmacy costs) were calculated.
Costs were adjusted to 2009 US dollars using the medical
care component of the Consumer Price Index.30 A Gener-
alized Linear Model (GLM) with a log-link function was used
to assess differences in costs. The model was used only to
account for the skewed nature of the costs while control-
ling for matched observations and did not include cova-
riates, since the matched cohorts were balanced at
baseline for the observed characteristics.
All statistical tests tested a two-sided hypothesis of no
difference between treatment groups at a significance level
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9.1.3 (SAS Institute; Cary, NC, USA).
Results
A total of 39,609 patients received a maintenance medi-
cation for COPD within 30 days of a qualifying index event
(Table 1). Of these, 35,459 (89.5%) were excluded from the
study due to lack of continuous enrollment (69.6%), receipt
of FSC in a non-study dose or budesonide/formoterol
(18.3%), presence of an exclusionary health condition
(22.1%) , or another reason. Of the remaining 4150 eligible
patients, 533 (12.8%) had received newly-initiated FSC
therapy within 30 days after the index event and the
remainder had received AC therapy, either as a continua-
tion of their pre-index event therapy or as new therapy.
Propensity score-matching at a ratio of 1:3 resulted in 484
patients in the final FSC cohort and 1452 patients in the AC
cohort.
Demographic and clinical characteristics
Prior to matching, the cohorts did not differ in age, but the
FSC cohort had a higher percentage of females (57% vs 52%;
P Z 0.035) and more comorbid asthma (19% vs 16%;
P Z 0.033) and upper respiratory tract infection (25% vs
21%; P Z 0.020) (data not shown). Prior to matching,
severity of disease was lower for the FSC cohort, as
reflected by fewer SABA canisters (1.2 vs 1.6; P Z 0.007)Table 1 Sample selection: attrition based on application
of eligibility criteria.
Eligibility criterion N (%)
Patients who received maintenance
therapy with FSC 250 mcg/50 mcg or
AC within 30 days after an index event
identified between January 1, 2004 and
January 31, 2008
39,609 (100%)
Reason for exclusion from study samplea
Age <40 years on the index date 405 (1.0%)
Not continuously enrolled in pre-index
and follow-up periods
27,570 (69.6%)
Received maintenance therapy with
ICS þ LABA in the pre-index period
11,558 (29.2%)
Disqualifying comorbid condition(s) 8742 (22.1%)
Received a prescription for budesonide/
formoterol or a non-study dose of FSC
(100/50 mcg or 500/50 mcg) during
the treatment assessment or
follow-up periods
7240 (18.3%)
Maintenance medication switch
in treatment assessment period
12,205 (30.8%)
Exacerbation in treatment
assessment period
5540 (14.0%)
Final sample 4150 (10.5%)
AC, anticholinergic; FSC, fluticasoneesalmeterol combination;
ICS, inhaled corticosteroid; LABA, long-acting beta-agonist.
a Criteria are not mutually exclusive; a patient may be
counted in more than one category.and oral corticosteroid prescriptions (0.5 vs 0.7; PZ 0.002)
and fewer classes of COPD maintenance medication during
the pre-index period (0.3 vs 0.5; P < 0.001). Prior to
matching, the proportion of patients with COPD-related
physician-outpatient visits during the pre-index period
was significantly lower for the FSC cohort than for the AC
cohort (11% vs 16%; PZ 0.002). Total COPD-related costs in
the pre-index period also were significantly higher for the
AC cohort than for the FSC cohort ($1198 vs $722;
P < 0.001) prior to matching, as were pharmacy costs ($574
vs $333; P < 0.001) and medical costs ($624 vs $389;
P Z 0.003).
Characteristics of the cohorts after matching are shown
in Table 2, and the distribution of standardized differences
for each covariate before and after matching is presented
in Fig. 1. After matching, standardized differences were
below the 10% threshold, indicating that the cohorts were
balanced in all observed variables used in the logistic
regression model to obtain the propensity score. After
matching there were no statistically significant differences
between groups in terms of occurrence of exacerbation in
the pre-index period, use of oral corticosteroids and SABA,
prevalence of asthma and other comorbidities, total
comorbidity score, COPD-related healthcare utilization and
costs, and other covariates. Standardized differences were
also reduced to less than 10% between cohorts for variables
not included in the PSM model, except that the mean
number of COPD-related “other outpatient” encounters
was lower in the FSC cohort than in the AC cohort (0.2 vs
0.4; standardized differenceZ 10.2%) (data not shown). In
the final cohorts, a total of 3% of study patients had
received LABA (FSC 4.3%, AC 1.9%), 5% had received ICS
(FSC 7.4%, AC 3.7%), 5% had received TIO (FSC 3.3%, AC
5.2%), and 21% had received IPR (FSC 17.8%, AC 21.5%) in
the pre-index period.Outcomes
The FSC cohort had a significantly lower proportion of
patients with a rehospitalization in the follow-up period
than did the AC cohort (3.1% vs 4.6%, PZ 0.047) (Table 3).
This was paralleled by a lower mean number of rehospi-
talizations in the FSC cohort (0.03 vs 0.07, P Z 0.001).
There were no differences between cohorts in the propor-
tion of patients with COPD-related exacerbations or in the
mean number of COPD-related exacerbations requiring ED
or physician-outpatient visits.
The FSC cohort also had lower COPD-related medical
costs ($1134 vs $1865, P < 0.001) but higher pharmacy costs
($946 vs $771, P Z 0.011) (Fig. 2). In spite of higher phar-
macy costs, total costs for the FSC cohort were significantly
lower than for the AC cohort ($2080 vs $2636, P Z 0.006).
A sensitivity analysis that excluded the matched sets of
AC and FSC patients in which any patient had received TIO
in the pre-index period (5% of patients) yielded similar
results to those of the primary analysis and did not change
the overall findings (Table 4).
Table 2 Baseline characteristics of cohorts after propensity score-matching.
FSC N Z 484 AC N Z 1452 P-valuea
Age (mean, SD)b 64.0 (9.8) 63.9 (9.9) 0.751
Female (n, %)b 265 (54.8%) 808 (55.7%) 0.646
Region (n, %)b
Midwest 85 (17.6%) 272 (18.7%) e
Northeast 213 (44.0%) 636 (43.8%) 0.313
South 139 (28.7%) 429 (29.6%) e
West 47 (9.7%) 115 (7.9%) e
Charlson comorbidity index (mean, SD)b 1.5 (1.9) 1.5 (2.0) 1.000
No. unique diagnoses (mean, SD)b 13.9 (10.1) 13.8 (10.5) 0.852
Asthma (n, %)b 79 (16.3%) 222 (15.3%) 0.464
Cardiovascular disease (n, %)b 279 (57.6%) 850 (58.5%) 0.650
Depression (n, %)b 67 (13.8%) 201 (13.8%) 1.000
Lower respiratory tract infection (n, %)b 146 (30.2%) 440 (30.3%) 0.968
Upper respiratory tract infection (n, %)b 105 (21.7%) 322 (22.2%) 0.782
No. prescription drug classes (mean, SD)b 8.4 (6.0) 8.4 (6.2) 0.795
No. prescriptions (mean, SD)b 9.3 (6.9) 9.2 (7.3) 0.772
SABA use (n, %)b 123 (25.4%) 376 (25.9%) 0.792
Oral corticosteroid use (n, %)b 123 (25.4%) 348 (24.0%) 0.386
No. maintenance medication classes (mean, SD)b 0.3 (0.6) 0.3 (0.6) 0.713
Home oxygen therapy (n, %)b 35 (7.2%) 91 (6.3%) 0.272
COPD exacerbation, pre-index period (n, %)b 77 (15.9%) 233 (16.1%) 0.958
COPD-related costs in pre-index period:
Medical costs (mean, SD) $416 ($1693) $389 ($1748) 0.668
Pharmacy costs (mean, SD) $339 ($685) $387 ($794) 0.060
Total costs (mean, SD) $756 ($1940) $776 ($2138) 0.781
Index event:
Hospitalization, COPD primary diagnosis 200 (41.3%) 593 (40.8%) e
Hospitalization, COPD secondary diagnosis 198 (40.9%) 595 (41.0%) 0.960
ED visit, COPD primary diagnosis 86 (17.8%) 264 (18.2%) e
AC, anticholinergic; COPD, chronic obstructive pulmonary disease; ED, emergency department; FSC, fluticasone propionate/salmeterol
combination (250 mcg/50 mcg); SABA, short-acting beta-agonist.
a P-values obtained from Wilcoxon signed-rank test for continuous variables and McNemar’s test for categorical variables.
b Variables used in the logistic regression model for propensity score-matching.
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In this “real world” retrospective study, 33% fewer FSC
patients than AC patients experienced a COPD-related
rehospitalization during the 12 months following a COPD
exacerbation. Healthcare costs were lower for the FSC
cohort as well. Although prescription drug costs for this
cohort were somewhat higher, savings from lower medical
costs more than offset the higher drug costs. Because this
was an observational study, we matched patients in each
cohort on propensity scores (propensity to receive FSC)
derived from their baseline characteristics in order to
reduce selection bias. The resulting cohorts were balanced
in terms of key covariates, including prevalence of comor-
bid asthma, SABA use, and prior COPD-related healthcare
utilization. These findings suggest that, following an exac-
erbation, combination ICS/LABA therapy may be preferable
to AC therapy for preventing subsequent exacerbations and
hospitalizations.
The direction of our findings is in general agreement
with other comparative effectiveness studies of FSC and
AC as maintenance therapy for COPD. Rascati and
colleagues found that compared to IPR therapy,ICS þ LABA therapy was associated with a 27% reduced risk
for any COPD-related event in a cohort of Medicaid
enrollees with COPD.31 In a separate Medicaid population,
patients receiving ICS þ LABA had a 35% lower risk for
COPD-related hospitalization compared to patients
receiving IPR therapy.32 Few studies have compared FSC to
TIO with regard to rehospitalization or exacerbation risk.
A retrospective study of Veterans Affairs patients reported
that compared to ICS þ LABA therapy, treatment with TIO
plus one or two other agents was associated with greater
risk for hospitalization (HR 1.85 and 1.81, respectively).33
A retrospective, observational study of an older pop-
ulation found that patients age 65 years who received
TIO as initial maintenance therapy had a 29% higher risk
for serious healthcare events (hospitalization or ED visit)
in the 12 months following therapy initiation than patients
who received FSC.34 However, in a randomized, double-
blind trial of 1323 patients, no difference in exacerba-
tion rates between FSC and TIO was observed.35 In that
study, the likelihood of withdrawal was 29% greater among
TIO patients, possibly resulting in a healthy survivor
effect. A retrospective study of maintenance therapies
among health plan members reported that risk for hospi-
talization and costs were lower for TIO than for FSC,
Table 3 COPD exacerbation events in the 12-month
follow-up period: fluticasone propionate/salmeterol versus
anticholinergics.
Outcome FSC
(N Z 484)
AC
(N Z 1452)
P-valuea
Patients with COPD exacerbation event (n, %)
Phy þ Rx 103 (21.3%) 305 (21.0%) 0.893
ED visit 34 (7.0%) 102 (7.0%) 1.000
Hospitalization 15 (3.1%) 67 (4.6%) 0.047
Hospitalization/ED 40 (8.3%) 146 (10.1%) 0.114
Hospitalization/
ED/Phy þ Rx
120 (24.8%) 396 (27.3%) 0.139
Number of COPD exacerbation events (mean, SD)
Phy þ Rx 0.32 (0.8) 0.35 (0.9) 0.583
ED 0.08 (0.3) 0.10 (0.5) 0.435
Hospitalization 0.03 (0.2) 0.07 (0.4) 0.001
Hospitalization/ED 0.11 (0.4) 0.17 (0.7) 0.033
Hospitalization/
ED/Phy þ Rx
0.43 (1.0) 0.51 (1.1) 0.094
COPD-related costs (mean, SD)
Medical $1134
($3223)
$1865
($8438)
<0.001
Pharmacy $946
($1097)
$771
($1058)
0.011
Total $2080
($3530)
$2636
($8657)
0.006
Medical cost breakdown
Hospitalization $404
(2678.2)
$895
(7953.9)
0.027
ED $69
(446.0)
$71
(389.8)
0.915
Physician/Outpatient $150
(269.2)
$165
(343.3)
0.185
Other Outpatient $180
(664.1)
$257
(967.8)
0.009
Other $332
(1093.8)
$477
(1497.9)
0.002
AC, anticholinergic; COPD; chronic obstructive pulmonary
disease; ED, emergency department; FSC, fluticasone proprio-
nate/salmeterol combination (250 mcg/50 mcg); Phy þ Rx,
physician-outpatient visit associated with an antibiotic or oral
corticosteroid prescription fill within 5 days.
a McNemar’s test used for risk of exacerbation; Wilcoxon’s
signed-rank test used for number of exacerbations and for costs
(obtained fromGLMmodelwith log-link and gammadistribution).
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Figure 1 Distribution of standardized differences in cohorts
at baseline and during pre-index period, before and after
propensity score-matching. Charlson, Charlson comorbidity
index; URTI, upper respiratory tract infection; LRTI, lower
respiratory tract infection; CVD, cardiovascular disease;
Rxclass_ct, number of unique prescription classes in pre-index
period; Rx_ct, number of prescriptions in pre-index period;
Dx_ct, number of unique diagnoses; Hosp_dx1, index event
was hospitalization with COPD primary diagnosis; Hosp_dx2,
index event was hospitalization with COPD secondary diag-
nosis; ED_dx, index event was ED visit with primary COPD
diagnosis; SABA, short-acting beta-agonist use; OCS, oral
corticosteroid use; Controller, controller medication use;
HomeOx, home oxygen use; ED_ex, COPD-related ED visit;
Hosp_ex, COPD-related hospitalization; Phy þ Rx_ex, COPD-
related physician-outpatient visit with antibiotic or oral corti-
costeroid prescription.
834 A.A. Dalal et al.formoterol, salmeterol or combination therapy with two
or more long-acting bronchodilators.36 The definitions of
a COPD diagnosis and exacerbation events in that study
differed from the present study, making direct compari-
sons difficult.
In our study, FSC therapy was associated with approxi-
mately 20% lower COPD-related healthcare costs than AC
therapy. These findings are similar to a recent retrospective
study that observed approximately 14% lower costs for FSC
compared to TIO and 15% lower costs for FSC compared to
IPR in the 12-month period following initiation of mainte-
nance therapy.37 In the present study, the savings observed
for FSC occurred despite slightly higher drug costs in this
cohort.
The proportion of patients who were rehospitalized
within 12 months of starting maintenance therapy (3.1% of
FSC patients and 4.6% of AC patients) was lower in this
study than others. Soriano and colleagues reported that
13.2% of recently hospitalized COPD patients who then
initiated maintenance therapy were readmitted within 12
months.18 Our lower rate could be due to rehospitalizations
occurring in hospitals not captured by the database we
used, although that is unlikely to explain the entire
difference. It should also be noted that Soriano included
admissions coded as pneumonia or lung infection, so our
rates are not directly comparable. A study in Canadian
hospitals found that 38% of patients (both those receiving
and not receiving maintenance therapy) were readmitted
within an average of five months.17
This study adds to the literature by directly comparing
the clinical and cost outcomes associated with treatmentwith different maintenance therapies in the year following
a serious COPD exacerbation. The study has several
strengths. We were careful to ensure that outcomes were
assessed only for FSC-naı¨ve patients. We excluded patients
with exacerbations or treatment changes within 30 days of
therapy initiation, which potentially ensured sufficient
time for newly-initiated therapy to take effect and avoided
potential confounding due to treatment switches. After the
30-day treatment assessment period, an intent-to-treat
approach was used similar to that used in clinical trials.
Crossover of treatments was minimal, in that less than 15%
and 20% of the FSC cohort were using TIO and IPR,
respectively, in the follow-up period. Correspondingly, 10%
of the AC cohort was using FSC in the follow-up period.
Table 4 Sensitivity analysis: COPD exacerbation events
after excluding patients with use of tiotropium in the pre-
index period, fluticasone propionate/salmeterol versus
anticholinergics.
Outcome FSC
(N Z 410)
AC
(N Z 1230)
P-valuea
Patients with COPD exacerbation event (n, %)
Phy þ Rx 79 (19.3%) 241 (19.6%) 0.880
ED 24 (5.9%) 90 (7.3%) 0.168
Hospitalization 10 (2.4%) 57 (4.6%) 0.005
Hospitalization/ED 27 (6.6%) 127 (10.3%) 0.001
Hospitalization/
ED/Phy þ Rx
92 (22.4%) 324 (26.3%) 0.027
Number of COPD exacerbation events (mean, SD)
Phy þ Rx 0.26 (0.6) 0.31 (0.8) 0.252
ED visit 0.07 (0.3) 0.11 (0.5) 0.041
Hospitalization 0.02 (0.2) 0.07 (0.4) <0.001
Hospitalization/ED 0.09 (0.4) 0.17 (0.7) 0.001
Hospitalization/
ED/Phy þ Rx
0.36 (0.8) 0.48 (1.1) 0.004
COPD-related costs (mean, SD)
Medical $1039
($3152)
$1753
($8449)
<0.05
Pharmacy $849
($978)
$682
($992)
0.013
Total $1889
($3414)
$2435
($8634)
0.008
Medical cost breakdown
Hospitalization $351
(2583.7)
$856
(8032.9)
0.020
ED $59
(439.0)
$71
(377.0)
0.155
Physician/Outpatient $139
(243.7)
$155
(338.6)
0.905
Other Outpatient $180
(684.3)
$254
(959.5)
0.126
Other $310
(1106.9)
$418
(1261.2)
0.014
AC, anticholinergic; COPD; chronic obstructive pulmonary
disease; ED, emergency department; FSC, fluticasone proprio-
nate/salmeterol combination (250 mcg/50 mcg); Phy þ Rx,
physician-outpatient visit associated with an antibiotic or oral
corticosteroid prescription fill within 5 days.
a McNemar’s test used for differences in prevalence of exac-
erbation event; Wilcoxon’s signed-rank test used for number of
exacerbation events and costs (obtained from GLM model with
log-link and gamma distribution).
Figure 2 COPD-related costs (costs in 2009 US dollars,
adjusted for inflation using Medical Care Component of
Consumer Price Index) in the 12-month follow-up period: fluti-
casone propionate/salmeterol versus anticholinergics. AC,
anticholinergic; ED, emergency department; FSC, fluticasone
propionate/salmeterol combination (250mcg/50mcg). *P< 0.05
compared to FSC.
COPD rehospitalization risk 835Therefore, the use of alternate medications after the
treatment assessment period was consistent in both
cohorts. Furthermore, there was sufficient sample size and
statistical power to employ a PSM method. Both multivar-
iate regression and PSM are accepted methods for handling
selection bias in non-randomized observational studies.
Using PSM ensured that the groups were balanced at
baseline in terms of potentially confounding clinical and
demographic characteristics.
The present study has limitations that should be
considered when interpreting results. Before matching, the
study cohorts differed on several baseline characteristics.
Because claims databases do not include lung function
information, COPD severity must be assessed using proxy
measures, such as frequency of use of rescue medication
(SABA), number of different COPD medications taken, and
presence of comorbidities. Using these proxy measures, we
matched patients on propensity score. To the extent that
these proxy measures are fairly representative of actual
COPD severity, the comparison of outcomes may be
considered valid between the matched cohorts. However,
after matching, residual confounding may exist if the
underlying severity is not adequately captured by these
proxy measures. Outcomes occurring in the treatment
assessment period were not counted in order to avoid
immortal time bias; this could have affected study results if
there were differences in outcomes between cohorts during
this period. Although the sensitivity analysis that excluded
patients with TIO in the pre-index period produced findings
similar to those of the main analysis, excluding patients
with prior use of short-acting AC was not feasible due to the
attritional impact of this criterion on sample size. Excluding
patients with prior ICS monotherapy or LABA monotherapy
(in the pre-index period) would not be expected to alter the
findings. Other limitations common in observational studies
using claims data include potential errors in the data, such
as miscoding or under-coding, and the inability to verify the
accuracy of diagnosis codes through review of patient
medical charts.Conclusions
In this study of COPD patients who received new mainte-
nance therapywith FSC or new or continuing therapywith AC
following an exacerbation, FSC was associated with signifi-
cantly fewer COPD-related rehospitalizations compared to
AC. Furthermore, COPD-related healthcare costs were lower
for the FSC cohort, even though prescription drug costs for
this cohort were higher. Savings from lower medical costs
more than offset the higher drug costs.
836 A.A. Dalal et al.Clinical guidelines recommend that ICS-containing
therapy be added to the drug regimen of patients experi-
encing frequent exacerbations. Following an exacerbation,
initiation of maintenance therapy with FSC, an ICS þ LABA
combination therapy, appears to have a more favorable
impact on subsequent healthcare utilization and cost
outcomes than does continued or new therapy with IPR or
TIO. For patients experiencing an exacerbation requiring
hospitalization, discharging them on appropriate mainte-
nance medication may be a key step in preventing subse-
quent exacerbations.Acknowledgments
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